Tanaka Masako, Shiota Masayuki, Nakao Takafumi, Uemura Ryo, Nishi Satoshi, Ohkawa Yasuyuki, Matsumoto Masaki, Yamaguchi Maki, Osada-Oka Mayuko, Inagaki Azusa, Takahashi Katsuyuki, Nakayama Keiichi I, Gi Min, Izumi Yasukatsu, Miura Katsuyuki, Iwao Hiroshi
Department of Pharmacology, Osaka City University Medical School, Osaka, Japan; Applied Pharmacology and Therapeutics, Osaka City University Medical School, Osaka, Japan.
Department of Pharmacology, Osaka City University Medical School, Osaka, Japan.
J Proteomics. 2016 Mar 16;136:214-21. doi: 10.1016/j.jprot.2016.01.008. Epub 2016 Jan 15.
Heat shock protein 72 (HSP72) is an intracellular molecular chaperone that is overexpressed in tumor cells, and has also been detected in extracellular regions such as the blood. HSP72 forms complexes with peptides and proteins that are released from tumors. Accordingly, certain HSP72-binding proteins/peptides present in the blood of cancer patients may be derived from tumor cells. In this study, to effectively identify low-abundance proteins/peptides in the blood as tumor markers, we established a method for isolating HSP72-binding proteins/peptides from serum. Nine HSP72-specific monoclonal antibodies were conjugated to N-hydroxysulfosuccinimide-activated Sepharose beads (NHq) and used to isolate HSP72 complexes from serum samples. Precipitated proteins were then identified by LC-MS/MS analysis. Notably, this approach enabled the isolation of low-abundance proteins from serum without albumin removal. Moreover, by subjecting the serum samples of ten patients with multiple myeloma (MM) to NHq analysis, we identified 299 proteins present in MM HSP72 complexes, including 65 intracellular proteins. Among the intracellular proteins detected, 21 were present in all serum samples tested, while 11 were detected in both the conditioned media from cultured multiple myeloma cells and serum from MM patients. These results suggest that the NHq method can be applied to discover candidate tumor markers.
热休克蛋白72(HSP72)是一种细胞内分子伴侣,在肿瘤细胞中过表达,在血液等细胞外区域也有检测到。HSP72与从肿瘤中释放的肽和蛋白质形成复合物。因此,癌症患者血液中存在的某些HSP72结合蛋白/肽可能来源于肿瘤细胞。在本研究中,为了有效识别血液中低丰度蛋白/肽作为肿瘤标志物,我们建立了一种从血清中分离HSP72结合蛋白/肽的方法。将9种HSP72特异性单克隆抗体与N-羟基琥珀酰亚胺活化的琼脂糖珠(NHq)偶联,并用于从血清样本中分离HSP72复合物。然后通过液相色谱-串联质谱分析鉴定沉淀的蛋白质。值得注意的是,这种方法能够在不去除白蛋白的情况下从血清中分离低丰度蛋白。此外,通过对10例多发性骨髓瘤(MM)患者的血清样本进行NHq分析,我们鉴定出MM HSP72复合物中存在的299种蛋白质,包括65种细胞内蛋白质。在所检测到的细胞内蛋白质中,21种存在于所有测试的血清样本中,11种在培养的多发性骨髓瘤细胞的条件培养基和MM患者的血清中均有检测到。这些结果表明,NHq方法可用于发现候选肿瘤标志物。